Rogers Corporation (ROG): Price and Financial Metrics


Rogers Corporation (ROG)

Today's Latest Price: $99.15 USD

2.87 (2.98%)

Updated Sep 28 2:15pm

Add ROG to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 37 in Technology - Electronics

See all "A" rated Strong Buy stocks

ROG Stock Summary

  • Rogers Corp's stock had its IPO on January 1, 1986, making it an older stock than 92.87% of US equities in our set.
  • ROG's current price/earnings ratio is 80.25, which is higher than 90.22% of US stocks with positive earnings.
  • The volatility of Rogers Corp's share price is greater than that of only 12.98% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Rogers Corp, a group of peers worth examining would be LIVN, CUB, RFL, HBIO, and MIND.
  • Visit ROG's SEC page to see the company's official filings. To visit the company's web site, go to www.rogerscorp.com.
ROG Daily Price Range
ROG 52-Week Price Range

ROG Stock Price Chart Technical Analysis Charts


ROG Price/Volume Stats

Current price $99.15 52-week high $157.10
Prev. close $96.28 52-week low $75.72
Day low $97.21 Volume 51,311
Day high $100.17 Avg. volume 135,368
50-day MA $116.53 Dividend yield N/A
200-day MA $113.96 Market Cap 1.85B

Rogers Corporation (ROG) Company Bio


Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The company was founded in 1832 and is based in Rogers, Connecticut.

ROG Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$99.15$67.62 -30%

Below please find a table outlining a discounted cash flow forecast for ROG, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Rogers Corp ranked in the 36th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 29.33%. As for the metrics that stood out in our discounted cash flow analysis of Rogers Corp, consider:

  • 89% of the company's capital comes from equity, which is greater than 75.7% of stocks in our cash flow based forecasting set.
  • The business' balance sheet suggests that 11% of the company's capital is sourced from debt; this is greater than merely 24.26% of the free cash flow producing stocks we're observing.
  • As a business, Rogers Corp experienced a tax rate of about 14% over the past twelve months; relative to its sector (Technology), this tax rate is higher than 61.31% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-31%
1%-30%
2%-30%
3%-29%
4%-28%
5%-28%

ACN, APH, OSIS, YY, and TER can be thought of as valuation peers to ROG, in the sense that they are in the Technology sector and have a similar price forecast based on DCF valuation.


ROG Latest News Stream


Event/Time News Detail
Loading, please wait...

ROG Latest Social Stream


Loading social stream, please wait...

View Full ROG Social Stream

Latest ROG News From Around the Web

Below are the latest news stories about Rogers Corp that investors may wish to consider to help them evaluate ROG as an investment opportunity.

Does Rogers' (NYSE:ROG) Share Price Gain of 89% Match Its Business Performance?

Rogers Corporation (NYSE:ROG) shareholders might be concerned after seeing the share price drop 14% in the last...

Yahoo | September 22, 2020

Better Buy: BCE (TSX:BCE), Telus (TSX:T), or Rogers (TSX:RCI.B)?

BCE Inc. (TSX:BCE)(NYSE:BCE) and the Canadian Big Three telecoms are now on sale amid the 5G boom, but are they worthy of your investment dollars? The post Better Buy: BCE (TSX:BCE), Telus (TSX:T), or Rogers (TSX:RCI.B)? appeared first on The Motley Fool Canada .

The Motley Fool Canada | September 19, 2020

Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments

There is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of clinical setbacks this summer seemed to close the door on the category’s potential.

Yahoo | September 18, 2020

Shares of Roche gain as it says arthritis drug can lessen need for ventilators in COVID-19 patients

Shares of Roche Holding AG gained 1.9% in premarket trading on Friday after the drug maker said hospitalized COVID-19 patients taking rheumatoid arthritis drug Actemra were less likely to need mechanical ventilation than those receiving placebo. The Phase 3, randomized, double-blind, placebo-controlled study focused on enrolling minority patients with COVID-19-related pneumonia; there are 389 participants enrolled in the trial. However, the drug did not lead to a difference in mortality, Roche said. Roche is also testing Actemra with Gilead Sciences Inc.'s remdesivir, which is the only new drug to receive an emergency use authorization from the Food and Drug Administration as a COVID-19 treatment during the pandemic. Earlier this week Eli Lilly & Co. and Incyte Corp. said their ...

Yahoo | September 18, 2020

Consumer goods drive record in seaborne imports to U.S. in August, and medical test kits may have peaked, report finds

Seaborne imports to the U.S. set a record in August and were up 5.9% from the same period a year ago, according to a new report from Panjiva, the supply chain research unit of S&P Global Market Intelligence.

Yahoo | September 9, 2020

Read More 'ROG' Stories Here

ROG Price Returns

1-mo -13.82%
3-mo -20.43%
6-mo 18.49%
1-year -26.23%
3-year -25.61%
5-year 86.44%
YTD -20.51%
2019 25.91%
2018 -38.82%
2017 110.81%
2016 48.94%
2015 -36.68%

Continue Researching ROG

Here are a few links from around the web to help you further your research on Rogers Corp's stock as an investment opportunity:

Rogers Corp (ROG) Stock Price | Nasdaq
Rogers Corp (ROG) Stock Quote, History and News - Yahoo Finance
Rogers Corp (ROG) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.893 seconds.